

## **II. CLAIM AMENDMENTS**

Claims 1-11 (Cancelled, without prejudice or disclaimer)

12. (Original Claim) A kit for providing neuromuscular block and its reversal comprising (a) an aminosteroidal neuromuscular blocking agent and (b) a reversal agent selected from the group consisting of  
6-per-deoxy-6-per-(2-carboxyethyl)thio- $\gamma$ -cyclodextrin;  
6-per-deoxy-6-per-(3-carboxypropyl)thio- $\gamma$ -cyclodextrin;  
6-per-deoxy-6-per-(4-carboxyphenyl)thio- $\gamma$ -cyclodextrin;  
6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio- $\gamma$ -cyclodextrin;  
6-per-deoxy-6-per-(2-carboxypropyl)thio- $\gamma$ -cyclodextrin; and  
6-per-deoxy-6-per-(2-sulfoethyl)thio- $\gamma$ -cyclodextrin;  
or a pharmaceutically acceptable salt thereof.

13. (Original Claim) A kit according to claim 1 wherein the aminosteroidal neuromuscular blocking agent is selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide and rapacuronium bromide, or another pharmaceutically acceptable salt thereof.

14. (Original Claim) A kit according to claim 2, wherein the neuromuscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6-per-(2-carboxyethyl)thio- $\gamma$ -cyclodextrin sodium salt.

15. (Original Claim) A method of treatment of a patient with a neuromuscular

blocking agent comprising the steps of (a) inducing the neuromuscular block by administration of an effective amount of an aminosteroidal blocking agent selected from the group consisting of rocuronium bromide, vecuronium bromide, pancuronium bromide and rapacuronium bromide, or another pharmaceutically acceptable salt thereof, and (b) reversing the drug-induced neuromuscular block by administration of an effective amount of at least one reversal agent selected from the group consisting of

6-per-deoxy-6-per-(2-carboxyethyl)thio- $\gamma$ -cyclodextrin;

6-per-deoxy-6-per-(3-carboxypropyl)thio- $\gamma$ -cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenyl)thio- $\gamma$ -cyclodextrin;

6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio- $\gamma$ -cyclodextrin;

6-per-deoxy-6-per-(2-carboxypropyl)thio- $\gamma$ -cyclodextrin; and

6-per-deoxy-6-per-(2-sulfoethyl)thio- $\gamma$ -cyclodextrin;

or a pharmaceutically acceptable salt thereof.

16. (Original Claim) The method of treatment according to claim 4, wherein the neuro-muscular blocking agent is rocuronium bromide and the reversal agent is 6-per-deoxy-6-per-(2-carboxyethyl)thio- $\gamma$ -cyclodextrin sodium salt.

### **III. SPECIFICATION AMENDMENTS**

(p. 2, l. 3, as a new line)

#### **Related Application**

This application claims priority from PCT/EP00/11789, filed November 23, 2000 and is a divisional of U.S. Application No. 10/148,307, filed May 29, 2002.

(p.2, l. 4, as a new line)

#### **Field of the Invention**

(p. 2, l. 8, as a new line)

#### **Background of the Invention**

(p. 4, l. 7, as a new line)

#### **Summary of the Invention**

(p. 5, l. 22, as a new line)

#### **Detailed Description of the Invention**

(p. 27, l.1)

**[Claims] We Claim:**